Centerpoint Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Centerpoint Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43K	Hold	87	–	–	0.01%	176
2026 Q1	$39K	Hold	87	–	–	0.01%	169
2025 Q4	$39K	Buy	87 +55	+172%	+$23.7K	0.01%	176
2025 Q3	$12K	Buy	+32	New	+$13.4K	﹤0.01%	322
2023 Q4	–	Sell	-4	Closed	-$1K	–	610
2023 Q3	$1K	Hold	4	–	–	﹤0.01%	551
2023 Q2	$1K	Hold	4	–	–	﹤0.01%	549
2023 Q1	$1K	Buy	+4	New	+$1.2K	﹤0.01%	541
2020 Q3	–	Sell	-73	Closed	-$21K	–	282
2020 Q2	$21K	Buy	+73	New	+$19.8K	0.02%	124

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Centerpoint Advisors's VRTX Position: Q2 2026 in Review

Centerpoint Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 87 shares worth $43K. The position accounts for 0.01% of the portfolio, ranked #176.

Centerpoint Advisors first reported a position in VRTX in Q2 2020 and has held it in 8 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Centerpoint Advisors held 87 shares of Vertex Pharmaceuticals worth $43K as of Q2 2026.
Centerpoint Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of Centerpoint Advisors's portfolio in Q2 2026, its #176 holding.
Centerpoint Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.